File Download
  • No File Attached
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Antioxidant therapy with Salvia miltiorrhiza decreases plasma endothelin-1 and thromboxane B2 after cardiopulmonary bypass in patients with congenital heart disease
  • Basic View
  • Metadata View
  • XML View
TitleAntioxidant therapy with Salvia miltiorrhiza decreases plasma endothelin-1 and thromboxane B2 after cardiopulmonary bypass in patients with congenital heart disease
 
AuthorsXia, Z1 2 2
Gu, J1
Ansley, DM2
Xia, F1
Yu, J1
 
Issue Date2003
 
PublisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/jtcvs
 
CitationJournal Of Thoracic And Cardiovascular Surgery, 2003, v. 126 n. 5, p. 1404-1410 [How to Cite?]
DOI: http://dx.doi.org/10.1016/S0022-5223(03)00970-X
 
AbstractObjective: The endothelium-derived vasoconstrictor endothelin-1 is increased after cardiopulmonary bypass in children with congenital heart defects. This study determines whether antioxidant therapy with Salvia miltiorrhiza injection, an herb extract containing phenolic compounds, prevents the postoperative increase of endothelin-1. The relationship between endothelin-1 and the endothelium-derived prostacyclin (prostaglandin I2) and thromboxane A2 postoperatively is also investigated. Methods: Twenty children with congenital heart defects and pulmonary hypertension were randomly assigned to group A (placebo control, n = 10) or B (200 mg/kg Salvia miltiorrhiza intravenously after anesthesia induction and at the time of rewarming, respectively; n = 10) before cardiac surgery. Central venous blood samples were taken before operation (T0), 10 (T1) and 30 minutes (T2) after starting cardiopulmonary bypass, 10 (T3) and 30 minutes (T4) after aortic declamping, and 30 minutes (T 55) and 24 hours (T6) after termination of cardiopulmonary bypass. Plasma lipid peroxidation product malondialdehyde, myocardial specific creatine kinase-MB activity, thromboxane B2, and 6-keto-prostaglandin F1α (stable metabolites of thromboxane A2 and prostaglandin I2) were measured. Results: Malondialdehyde increased significantly at T1 in group A and remained significantly higher than in group B thereafter (P < .05). Malondialdehyde in group B did not significantly increase over time. At T5, plasma creatine kinase-MB, thromboxane B2, and endothelin-1 in group B were lower than in group A (P < .05); malondialdehyde correlated significantly with creatine kinase-MB (r = 0.71, P = .0005). At T6, endothelin-1 negatively correlated with the 6-keto-prostaglandin F1α/thromboxane B2 ratio (r = -0.64, P = .0025). Conclusion: Antioxidant therapy reduces myocardial damage and attenuates postoperative vasoactive mediator imbalance.
 
ISSN0022-5223
2012 Impact Factor: 3.526
2012 SCImago Journal Rankings: 1.730
 
DOIhttp://dx.doi.org/10.1016/S0022-5223(03)00970-X
 
ISI Accession Number IDWOS:000186722600028
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorXia, Z
 
dc.contributor.authorGu, J
 
dc.contributor.authorAnsley, DM
 
dc.contributor.authorXia, F
 
dc.contributor.authorYu, J
 
dc.date.accessioned2012-05-29T06:00:46Z
 
dc.date.available2012-05-29T06:00:46Z
 
dc.date.issued2003
 
dc.description.abstractObjective: The endothelium-derived vasoconstrictor endothelin-1 is increased after cardiopulmonary bypass in children with congenital heart defects. This study determines whether antioxidant therapy with Salvia miltiorrhiza injection, an herb extract containing phenolic compounds, prevents the postoperative increase of endothelin-1. The relationship between endothelin-1 and the endothelium-derived prostacyclin (prostaglandin I2) and thromboxane A2 postoperatively is also investigated. Methods: Twenty children with congenital heart defects and pulmonary hypertension were randomly assigned to group A (placebo control, n = 10) or B (200 mg/kg Salvia miltiorrhiza intravenously after anesthesia induction and at the time of rewarming, respectively; n = 10) before cardiac surgery. Central venous blood samples were taken before operation (T0), 10 (T1) and 30 minutes (T2) after starting cardiopulmonary bypass, 10 (T3) and 30 minutes (T4) after aortic declamping, and 30 minutes (T 55) and 24 hours (T6) after termination of cardiopulmonary bypass. Plasma lipid peroxidation product malondialdehyde, myocardial specific creatine kinase-MB activity, thromboxane B2, and 6-keto-prostaglandin F1α (stable metabolites of thromboxane A2 and prostaglandin I2) were measured. Results: Malondialdehyde increased significantly at T1 in group A and remained significantly higher than in group B thereafter (P < .05). Malondialdehyde in group B did not significantly increase over time. At T5, plasma creatine kinase-MB, thromboxane B2, and endothelin-1 in group B were lower than in group A (P < .05); malondialdehyde correlated significantly with creatine kinase-MB (r = 0.71, P = .0005). At T6, endothelin-1 negatively correlated with the 6-keto-prostaglandin F1α/thromboxane B2 ratio (r = -0.64, P = .0025). Conclusion: Antioxidant therapy reduces myocardial damage and attenuates postoperative vasoactive mediator imbalance.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationJournal Of Thoracic And Cardiovascular Surgery, 2003, v. 126 n. 5, p. 1404-1410 [How to Cite?]
DOI: http://dx.doi.org/10.1016/S0022-5223(03)00970-X
 
dc.identifier.doihttp://dx.doi.org/10.1016/S0022-5223(03)00970-X
 
dc.identifier.epage1410
 
dc.identifier.isiWOS:000186722600028
 
dc.identifier.issn0022-5223
2012 Impact Factor: 3.526
2012 SCImago Journal Rankings: 1.730
 
dc.identifier.issue5
 
dc.identifier.pmid14666012
 
dc.identifier.scopuseid_2-s2.0-0344494039
 
dc.identifier.spage1404
 
dc.identifier.urihttp://hdl.handle.net/10722/147205
 
dc.identifier.volume126
 
dc.languageeng
 
dc.publisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/jtcvs
 
dc.publisher.placeUnited States
 
dc.relation.ispartofJournal of Thoracic and Cardiovascular Surgery
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAdolescent
 
dc.subject.meshAntioxidants - Administration & Dosage
 
dc.subject.meshBiological Assay
 
dc.subject.meshCardiac Surgical Procedures - Methods
 
dc.subject.meshCardiopulmonary Bypass - Adverse Effects - Methods
 
dc.subject.meshChemotherapy, Adjuvant
 
dc.subject.meshChild
 
dc.subject.meshChild, Preschool
 
dc.subject.meshConfidence Intervals
 
dc.subject.meshDose-Response Relationship, Drug
 
dc.subject.meshDouble-Blind Method
 
dc.subject.meshDrug Administration Schedule
 
dc.subject.meshEndothelin-1 - Blood
 
dc.subject.meshFemale
 
dc.subject.meshHeart Defects, Congenital - Diagnosis - Drug Therapy - Surgery
 
dc.subject.meshHumans
 
dc.subject.meshInfusions, Intravenous
 
dc.subject.meshIntraoperative Period
 
dc.subject.meshMale
 
dc.subject.meshMultivariate Analysis
 
dc.subject.meshPhytotherapy - Methods
 
dc.subject.meshPostoperative Complications - Prevention & Control
 
dc.subject.meshProbability
 
dc.subject.meshPrognosis
 
dc.subject.meshSalvia Miltiorrhiza
 
dc.subject.meshSensitivity And Specificity
 
dc.subject.meshSeverity Of Illness Index
 
dc.subject.meshThromboxane B2 - Blood
 
dc.subject.meshTreatment Outcome
 
dc.titleAntioxidant therapy with Salvia miltiorrhiza decreases plasma endothelin-1 and thromboxane B2 after cardiopulmonary bypass in patients with congenital heart disease
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Xia, Z</contributor.author>
<contributor.author>Gu, J</contributor.author>
<contributor.author>Ansley, DM</contributor.author>
<contributor.author>Xia, F</contributor.author>
<contributor.author>Yu, J</contributor.author>
<date.accessioned>2012-05-29T06:00:46Z</date.accessioned>
<date.available>2012-05-29T06:00:46Z</date.available>
<date.issued>2003</date.issued>
<identifier.citation>Journal Of Thoracic And Cardiovascular Surgery, 2003, v. 126 n. 5, p. 1404-1410</identifier.citation>
<identifier.issn>0022-5223</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/147205</identifier.uri>
<description.abstract>Objective: The endothelium-derived vasoconstrictor endothelin-1 is increased after cardiopulmonary bypass in children with congenital heart defects. This study determines whether antioxidant therapy with Salvia miltiorrhiza injection, an herb extract containing phenolic compounds, prevents the postoperative increase of endothelin-1. The relationship between endothelin-1 and the endothelium-derived prostacyclin (prostaglandin I2) and thromboxane A2 postoperatively is also investigated. Methods: Twenty children with congenital heart defects and pulmonary hypertension were randomly assigned to group A (placebo control, n = 10) or B (200 mg/kg Salvia miltiorrhiza intravenously after anesthesia induction and at the time of rewarming, respectively; n = 10) before cardiac surgery. Central venous blood samples were taken before operation (T0), 10 (T1) and 30 minutes (T2) after starting cardiopulmonary bypass, 10 (T3) and 30 minutes (T4) after aortic declamping, and 30 minutes (T 55) and 24 hours (T6) after termination of cardiopulmonary bypass. Plasma lipid peroxidation product malondialdehyde, myocardial specific creatine kinase-MB activity, thromboxane B2, and 6-keto-prostaglandin F1&#945; (stable metabolites of thromboxane A2 and prostaglandin I2) were measured. Results: Malondialdehyde increased significantly at T1 in group A and remained significantly higher than in group B thereafter (P &lt; .05). Malondialdehyde in group B did not significantly increase over time. At T5, plasma creatine kinase-MB, thromboxane B2, and endothelin-1 in group B were lower than in group A (P &lt; .05); malondialdehyde correlated significantly with creatine kinase-MB (r = 0.71, P = .0005). At T6, endothelin-1 negatively correlated with the 6-keto-prostaglandin F1&#945;/thromboxane B2 ratio (r = -0.64, P = .0025). Conclusion: Antioxidant therapy reduces myocardial damage and attenuates postoperative vasoactive mediator imbalance.</description.abstract>
<language>eng</language>
<publisher>Mosby, Inc. The Journal&apos;s web site is located at http://www.elsevier.com/locate/jtcvs</publisher>
<relation.ispartof>Journal of Thoracic and Cardiovascular Surgery</relation.ispartof>
<subject.mesh>Adolescent</subject.mesh>
<subject.mesh>Antioxidants - Administration &amp; Dosage</subject.mesh>
<subject.mesh>Biological Assay</subject.mesh>
<subject.mesh>Cardiac Surgical Procedures - Methods</subject.mesh>
<subject.mesh>Cardiopulmonary Bypass - Adverse Effects - Methods</subject.mesh>
<subject.mesh>Chemotherapy, Adjuvant</subject.mesh>
<subject.mesh>Child</subject.mesh>
<subject.mesh>Child, Preschool</subject.mesh>
<subject.mesh>Confidence Intervals</subject.mesh>
<subject.mesh>Dose-Response Relationship, Drug</subject.mesh>
<subject.mesh>Double-Blind Method</subject.mesh>
<subject.mesh>Drug Administration Schedule</subject.mesh>
<subject.mesh>Endothelin-1 - Blood</subject.mesh>
<subject.mesh>Female</subject.mesh>
<subject.mesh>Heart Defects, Congenital - Diagnosis - Drug Therapy - Surgery</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Infusions, Intravenous</subject.mesh>
<subject.mesh>Intraoperative Period</subject.mesh>
<subject.mesh>Male</subject.mesh>
<subject.mesh>Multivariate Analysis</subject.mesh>
<subject.mesh>Phytotherapy - Methods</subject.mesh>
<subject.mesh>Postoperative Complications - Prevention &amp; Control</subject.mesh>
<subject.mesh>Probability</subject.mesh>
<subject.mesh>Prognosis</subject.mesh>
<subject.mesh>Salvia Miltiorrhiza</subject.mesh>
<subject.mesh>Sensitivity And Specificity</subject.mesh>
<subject.mesh>Severity Of Illness Index</subject.mesh>
<subject.mesh>Thromboxane B2 - Blood</subject.mesh>
<subject.mesh>Treatment Outcome</subject.mesh>
<title>Antioxidant therapy with Salvia miltiorrhiza decreases plasma endothelin-1 and thromboxane B2 after cardiopulmonary bypass in patients with congenital heart disease</title>
<type>Article</type>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1016/S0022-5223(03)00970-X</identifier.doi>
<identifier.pmid>14666012</identifier.pmid>
<identifier.scopus>eid_2-s2.0-0344494039</identifier.scopus>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-0344494039&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>126</identifier.volume>
<identifier.issue>5</identifier.issue>
<identifier.spage>1404</identifier.spage>
<identifier.epage>1410</identifier.epage>
<identifier.isi>WOS:000186722600028</identifier.isi>
<publisher.place>United States</publisher.place>
</item>
Author Affiliations
  1. Hubei General Hospital
  2. The University of British Columbia